BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 27, 2007
View Archived Issues
Recent patents describe new treatments for ADHD, depression and anxiety
Read More
Tarantula-derived peptide shows analgesic effects via ASIC blockade and activation of opioid system
Read More
Squalestatin protects neurons in culture from Abeta toxicity
Read More
Janssen-Cilag submits MAA for ceftobiprole to Swissmedic
Read More
Potential disease-modifying anti-AD drugs discovered under a Wyeth/ArQule collaboration
Read More
Series of nonsteroidal SARMs discovered at GSK
Read More
Potent and selective PPARalpha activator emerges from SAR program at BMS
Read More
Patient enrollment in phase III trial of QUATRx's Ophena completed
Read More
Systems Medicine and NCI enter cancer R&D agreement
Read More
Thallion completes phase I/II trial of ECO-4601 for advanced cancer
Read More
Vical reports results from a series of pDNA vaccine phase IIa trials for HIV
Read More
Teijin and Chugai agree to codevelop Ipsen's antidiabetic medicine in Japan
Read More
Enrollment for Medidur human PK study commences
Read More
Med Discovery and Draximage embark on research collaboration
Read More
New treatments for gynecological disorders disclosed in recent Lilly patent
Read More
Roche's Avastin approved in E.U. for first-line treatment of NSCLC patients
Read More
MHLW approves additional dosage and administration for PPIs
Read More
Cephalon acquires North American rights to Amrix from ECR
Read More
First patients enrolled in AtheroGenics phase III diabetes trial of AGI-1067
Read More
FDA approves Risperdal for schizophrenia and short-term bipolar mania in adolescents
Read More
Regeneron and sanofi-aventis begin phase III aflibercept oncology program
Read More
AstraZeneca begins phase IIb trial of AZD-3480 for schizophrenia
Read More
Novartis' Rasilez approved in the E.U. for high blood pressure
Read More
Novel SARMs designed by Merck as potential osteoanabolic agents
Read More
New class of small-molecule MCH-R1 antagonists reported by Schering-Plough
Read More
Dual CRTH2/DP receptor antagonist selected as development candidate at Amgen
Read More
Schering-Plough synthesizes and characterizes novel NK1 antagonists for emesis
Read More
BMS continues to search for improved IGF-1R kinase inhibitors
Read More